Lupin Limited Annual Report 2024 2024. S&p global csa score 2023: The local anesthesia drugs market size has grown strongly in recent years.


Lupin Limited Annual Report 2024 2024

Lupin’s revenue came in at rs 5,197.4 crore. Revenue increased by 12% to rs 4,961 crore.

Lupin Reported A 52% Yoy Growth In Net Profit To Rs 368 Crore For March 2024 Quarter.

G lobal pharma major lupin limited has announced its debut in the s&p global sustainability yearbook 2024, underscoring its dedication to corporate.

The Analysts Expect The Pharma Company's Quarterly Revenue To Grow 16.4 Per Cent To Rs 5,156 Crore.

It will grow from $1.48 billion in 2023 to $1.62 billion in 2024 at a compound annual growth.

Contributed Around 70% To Lupin's Total Revenue.

Images References :

February 07, 2024 / 09:30 Pm Ist.

Q4 results 6 may 2024 updates:

Lupinโ€™s Consolidated Revenues For The Financial Year 2023 Stood At โ‚น16,641 Crore Compared To โ‚น16,405 Crore In Fy22, With A Net Profit Of โ‚น430 Crore In Fy23.

Lupin limited to report q2, 2024 results on nov 08, 2023 oct 26 lupin limited receives tentative approval from u.s.

Download Now Visit Esg Microsite.